Cargando…
The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology
Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076726/ https://www.ncbi.nlm.nih.gov/pubmed/37033980 http://dx.doi.org/10.3389/fimmu.2023.1089098 |
_version_ | 1785020196741709824 |
---|---|
author | Zutautas, Katherine B. Sisnett, Danielle J. Miller, Jessica E. Lingegowda, Harshavardhan Childs, Timothy Bougie, Olga Lessey, Bruce A. Tayade, Chandrakant |
author_facet | Zutautas, Katherine B. Sisnett, Danielle J. Miller, Jessica E. Lingegowda, Harshavardhan Childs, Timothy Bougie, Olga Lessey, Bruce A. Tayade, Chandrakant |
author_sort | Zutautas, Katherine B. |
collection | PubMed |
description | Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation, and infertility. Alterations to Leukemia Inhibitory Factor (LIF), a cytokine produced by the luminal and glandular epithelium of the endometrium that is imperative for successful pregnancy, have been postulated to contribute to infertility. Conditions such as recurrent implantation failure, unexplained infertility, and infertility associated diseases such as adenomyosis and endometriosis, have demonstrated reduced LIF production in the endometrium of infertile patients compared to fertile counterparts. While this highlights the potential involvement of LIF in infertility, LIF is a multifaceted cytokine which plays additional roles in the maintenance of cell stemness and immunomodulation. Thus, we sought to explore the implications of LIF production within ectopic lesions on endometriosis pathophysiology. Through immunohistochemistry of an endometrioma tissue microarray and ELISA of tissue protein extract and peritoneal fluid samples, we identify LIF protein expression in the ectopic lesion microenvironment. Targeted RT qPCR for LIF and associated signaling transcripts, identify LIF to be significantly downregulated in the ectopic tissue compared to eutopic and control while its receptor, LIFR, is upregulated, highlighting a discordance in ectopic protein and mRNA LIF expression. In vitro treatment of endometriosis representative cell lines (12Z and hESC) with LIF increased production of immune-recruiting cytokines (MCP-1, MCP-3) and the angiogenic factor, VEGF, as well as stimulated tube formation in human umbilical vein endothelial cells (HUVECs). Finally, LIF treatment in a syngeneic mouse model of endometriosis induced both local and peripheral alterations to immune cell phenotypes, ultimately reducing immunoregulatory CD206(+) small peritoneal macrophages and T regulatory cells. These findings suggest that LIF is present in the ectopic lesions of endometriosis patients and could be contributing to lesion vascularization and immunomodulation. |
format | Online Article Text |
id | pubmed-10076726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100767262023-04-07 The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology Zutautas, Katherine B. Sisnett, Danielle J. Miller, Jessica E. Lingegowda, Harshavardhan Childs, Timothy Bougie, Olga Lessey, Bruce A. Tayade, Chandrakant Front Immunol Immunology Endometriosis is an estrogen dominant, chronic inflammatory disease characterized by the growth of endometrial-like tissue outside of the uterus. The most common symptoms experienced by patients include manifestations of chronic pelvic pain- such as pain with urination, menstruation, or defecation, and infertility. Alterations to Leukemia Inhibitory Factor (LIF), a cytokine produced by the luminal and glandular epithelium of the endometrium that is imperative for successful pregnancy, have been postulated to contribute to infertility. Conditions such as recurrent implantation failure, unexplained infertility, and infertility associated diseases such as adenomyosis and endometriosis, have demonstrated reduced LIF production in the endometrium of infertile patients compared to fertile counterparts. While this highlights the potential involvement of LIF in infertility, LIF is a multifaceted cytokine which plays additional roles in the maintenance of cell stemness and immunomodulation. Thus, we sought to explore the implications of LIF production within ectopic lesions on endometriosis pathophysiology. Through immunohistochemistry of an endometrioma tissue microarray and ELISA of tissue protein extract and peritoneal fluid samples, we identify LIF protein expression in the ectopic lesion microenvironment. Targeted RT qPCR for LIF and associated signaling transcripts, identify LIF to be significantly downregulated in the ectopic tissue compared to eutopic and control while its receptor, LIFR, is upregulated, highlighting a discordance in ectopic protein and mRNA LIF expression. In vitro treatment of endometriosis representative cell lines (12Z and hESC) with LIF increased production of immune-recruiting cytokines (MCP-1, MCP-3) and the angiogenic factor, VEGF, as well as stimulated tube formation in human umbilical vein endothelial cells (HUVECs). Finally, LIF treatment in a syngeneic mouse model of endometriosis induced both local and peripheral alterations to immune cell phenotypes, ultimately reducing immunoregulatory CD206(+) small peritoneal macrophages and T regulatory cells. These findings suggest that LIF is present in the ectopic lesions of endometriosis patients and could be contributing to lesion vascularization and immunomodulation. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076726/ /pubmed/37033980 http://dx.doi.org/10.3389/fimmu.2023.1089098 Text en Copyright © 2023 Zutautas, Sisnett, Miller, Lingegowda, Childs, Bougie, Lessey and Tayade https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zutautas, Katherine B. Sisnett, Danielle J. Miller, Jessica E. Lingegowda, Harshavardhan Childs, Timothy Bougie, Olga Lessey, Bruce A. Tayade, Chandrakant The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title | The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title_full | The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title_fullStr | The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title_full_unstemmed | The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title_short | The dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
title_sort | dysregulation of leukemia inhibitory factor and its implications for endometriosis pathophysiology |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076726/ https://www.ncbi.nlm.nih.gov/pubmed/37033980 http://dx.doi.org/10.3389/fimmu.2023.1089098 |
work_keys_str_mv | AT zutautaskatherineb thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT sisnettdaniellej thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT millerjessicae thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT lingegowdaharshavardhan thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT childstimothy thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT bougieolga thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT lesseybrucea thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT tayadechandrakant thedysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT zutautaskatherineb dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT sisnettdaniellej dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT millerjessicae dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT lingegowdaharshavardhan dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT childstimothy dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT bougieolga dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT lesseybrucea dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology AT tayadechandrakant dysregulationofleukemiainhibitoryfactoranditsimplicationsforendometriosispathophysiology |